Drug Profile

OTOF GT

Alternative Names: OTOF-GT; SENS-501

Latest Information Update: 30 Sep 2024

Price :

$50 ^*

Note:

Adis is an information provider. We do not sell or distribute actual drugs.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

Originator Institut Pasteur
Developer Sensorion
Class Gene therapies
Mechanism of Action Gene transference; OTOF protein expression modulators

Orphan Drug Status

Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

Yes - Deafness
New Molecular Entity No

Highest Development Phases

Phase I/II Deafness

Most Recent Events

23 Sep 2024 Efficacy data from a phase I/II trial in Deafness released by Sensorion
20 Sep 2024 Adverse event data from a phase I/II trial in Deafness released by Sensorion
11 Sep 2024 European Medicines Agency (EMA) approves the pediatric investigation plan for Deafness

You need to be a logged in or subscribed to view this content

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com